FDA Analysis of Pembrolizumab Trials in Multiple Myeloma: Immune Related Adverse Events (irAEs) and Response

A team from the U.S. Food and Drug Administration and the National Cancer Institute analyzed overall survival, safety, and objective response rates among patients with relapsed/refractory multiple myeloma (MM; KEYNOTE-183) and newly diagnosed MM (KEYNOTE-185) who developed immune-related adverse events vs those who didn’t during treatment with pembrolizumab plus chemotherapy.

American Society of Clinical Oncology 2018 Annual Meeting Abstract